| scholarly article | Q13442814 |
| P50 | author | Lynne Mofenson | Q43882680 |
| P2093 | author name string | D Bray | |
| T Fleming | |||
| M Mirochnick | |||
| P Miotti | |||
| J B Jackson | |||
| M Allen | |||
| C Nakabiito | |||
| D Bagenda | |||
| F Mmiro | |||
| M G Fowler | |||
| P Musoke | |||
| J Sherman | |||
| C Ducar | |||
| K Dransfield | |||
| L A Guay | |||
| L Emel | |||
| M Deseyve | |||
| P Bakaki | |||
| P2860 | cites work | Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire | Q45767653 |
| Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group | Q45790196 | ||
| International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Ghent International Working Group on Mother-to-Child Transmission of HIV. | Q46357586 | ||
| Mother-to-child transmission of HIV: implications of variation in maternal infectivity. | Q46631963 | ||
| Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial | Q64131584 | ||
| Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group | Q64131586 | ||
| Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group | Q28239283 | ||
| Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group | Q34736939 | ||
| Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo | Q35854030 | ||
| A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). | Q38886823 | ||
| Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa | Q39217507 | ||
| HIV transmission through breastfeeding: a study in Malawi | Q43460592 | ||
| 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study G | Q43935041 | ||
| Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team | Q45754372 | ||
| P433 | issue | 9181 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Uganda | Q1036 |
| zidovudine | Q198504 | ||
| nevirapine | Q263713 | ||
| prevention of HIV/AIDS | Q7242372 | ||
| HIV transmission | Q49029021 | ||
| P304 | page(s) | 795-802 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial | |
| P478 | volume | 354 |
| Q36467686 | (C2) Saliva, breast milk, and mucosal fluids in HIV transmission |
| Q35840375 | A Paradigm Shift in the Epidemiology of HIV in Pregnancy at ICTC of a Medical College |
| Q42284179 | A case report of evaluating a large-scale health systems improvement project in an uncontrolled setting: a quality improvement initiative in KwaZulu-Natal, South Africa |
| Q39726519 | A catastrophe in the 21st century: the public health situation in South Africa following HIV/AIDS. |
| Q33351797 | A coarsened multinomial regression model for perinatal mother to child transmission of HIV. |
| Q34376069 | A comparative analysis of teenagers and older pregnant women in the utilization of prevention of mother to child transmission [PMTCT] services in, Western Nigeria |
| Q35792581 | A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study". |
| Q36286901 | A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection |
| Q33848604 | A grander challenge: the case of how Makerere University College of Health Sciences (MakCHS) contributes to health outcomes in Africa |
| Q35990085 | A history of pediatric immunology |
| Q33437713 | A liquid chromatography/atmospheric pressure ionization tandem mass spectrometry quantitation method for nevirapine and its two oxidative metabolites, 2-hydroxynevirapine and nevirapine 4-carboxylic acid, and pharmacokinetics in baboons |
| Q35531092 | A pilot study to evaluate the safety and feasibility of the administration of AZT/3TC fixed dose combination to HIV infected pregnant women and their infants in Rio de Janeiro, Brazil |
| Q35180669 | A qualitative analysis of the barriers and facilitators to receiving care in a prevention of mother-to-child program in Nkhoma, Malawi |
| Q28469347 | A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women |
| Q35245932 | A reversal in reductions of child mortality in western Kenya, 2003-2009. |
| Q33514519 | A sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboons |
| Q35615036 | A study to determine the incidence and prevalence of newly discovered human immunodeficiency virus infection during the prenatal care period |
| Q33215941 | A validated new method for nevirapine quantitation in human plasma via high-performance liquid chromatography |
| Q33865715 | A whole genome association study of mother-to-child transmission of HIV in Malawi |
| Q33957973 | A window into a public program for prevention of mother to child transmission of HIV: evidence from a prospective clinical trial |
| Q46810449 | AIDS drug trials in Thailand and Uganda |
| Q42045726 | AIDS in Africa: a disaster no longer waiting to happen |
| Q57552357 | AIDS in AfricaHIV Exceptionalism: Development through Disease in Sierra Leone, by BentonAdia. Minneapolis: University of Minnesota Press, 2015. 176 pp. $22.50 paper. ISBN: 9780816692439.Letting Them Die: Why AIDS Prevention Programmes Fail, by Campbe |
| Q36760093 | AIDS in pregnancy, part II: Treatment in the era of highly active antiretroviral therapy and management of obstetric, anesthetic, and pediatric issues |
| Q38871928 | ASSESSING THE ASSOCIATION BETWEEN TRENDS IN A BIOMARKER AND RISK OF EVENT WITH AN APPLICATION IN PEDIATRIC HIV/AIDS. |
| Q39173174 | Abstinence Funding Was Not Associated With Reductions In HIV Risk Behavior In Sub-Saharan Africa |
| Q34989216 | Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations |
| Q38876072 | Acceptance of HIV testing among women attending antenatal care in south-western Uganda: risk factors and reasons for test refusal |
| Q36711428 | Acceptance of Voluntary Counselling, Testing and Treatment for HIV Among Pregnant Women in Kumasi, Ghana |
| Q37660215 | Access to HIV/AIDS care for mothers and children in sub-Saharan Africa: adherence to the postnatal PMTCT program |
| Q35166839 | Accomplishments in HIV prevention science: implications for stemming the epidemic |
| Q45199508 | Activists and researchers rally behind AIDS drug for mothers |
| Q92746907 | Adapting the HIV Infant Tracking System to Support Prevention of Mother-to-Child Transmission of HIV in Kenya: Protocol for an Intervention Development Pilot Study in Two Hospitals |
| Q34033166 | Addition of 7 Days of Zidovudine Plus Lamivudine to Peripartum Single-Dose Nevirapine Effectively Reduces Nevirapine Resistance Postpartum in HIV-Infected Mothers in Malawi |
| Q33795600 | Addressing missing data in clinical trials |
| Q40390193 | Addressing the paediatric HIV epidemic: a perspective from the Western Cape Region of South Africa |
| Q28478531 | Adherence to combination prophylaxis for prevention of mother-to-child-transmission of HIV in Tanzania |
| Q37256067 | Advances and failures in preventing perinatal human immunodeficiency virus infection |
| Q33958977 | Advances and research directions in the prevention of mother-to-child HIV-1 transmission |
| Q37800840 | Advances in Prevention of Mother-to-Child HIV Transmission: The International Perspectives |
| Q39953417 | Advances in human clinical trials of vaccines to prevent HIV/AIDS and other HIV prevention interventions |
| Q35673592 | Advances in prevention of mother-to-child HIV transmission |
| Q38267557 | Adverse drug reactions associated with antiretroviral therapy during pregnancy |
| Q34071132 | Adverse effects of antiretroviral therapy |
| Q38870249 | Adverse events and placebo effects: African scientists, HIV, and ethics in the 'global health sciences'. |
| Q43583268 | Altered vaginal microbiota are associated with perinatal mother-to-child transmission of HIV in African women from Burkina Faso. |
| Q34059986 | Analysis of HIV diversity using a high-resolution melting assay |
| Q30558708 | Analysis of HIV early infant diagnosis data to estimate rates of perinatal HIV transmission in Zambia |
| Q34786687 | Analysis of HIV tropism in Ugandan infants |
| Q33874942 | Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda |
| Q36983684 | Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. |
| Q36926027 | Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq). |
| Q34790188 | Animal models of anti-HIV drugs exposure during pregnancy: effects on neurobehavioral development |
| Q44529631 | Antenatal and perinatal strategies to prevent mother-to-child transmission of HIV infection |
| Q44098419 | Antenatal vitamin A supplementation increases birth weight and decreases anemia among infants born to human immunodeficiency virus-infected women in Malawi. |
| Q73071285 | Anti-HIV therapy during pregnancy: risk-benefit ratio |
| Q37809609 | Antiretroviral Pharmacology: Special Issues Regarding Pregnant Women and Neonates |
| Q36873010 | Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis |
| Q37115759 | Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy |
| Q27014960 | Antiretroviral drug regimens to prevent mother-to-child transmission of HIV: a review of scientific, program, and policy advances for sub-Saharan Africa |
| Q33897042 | Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity |
| Q34344415 | Antiretroviral drugs in pediatrics |
| Q24243370 | Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high risk individuals |
| Q24201955 | Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals |
| Q21144657 | Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice |
| Q34085343 | Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs |
| Q33512906 | Antiretroviral strategies to prevent mother-to-child transmission of HIV: striking a balance between efficacy, feasibility, and resistance |
| Q24236763 | Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women |
| Q34074272 | Antiretroviral therapy 2000. |
| Q36681036 | Antiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine |
| Q34346305 | Antiretroviral therapy in pregnancy: a focus on safety |
| Q77938624 | Antiretroviral therapy in pregnant women of Florence |
| Q35557314 | Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives? |
| Q33294899 | Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach |
| Q35826189 | Antiretroviral treatment of maternal HIV infection |
| Q34394712 | Antiretroviral treatments to reduce mother-to-child transmission of HIV. |
| Q24235500 | Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection |
| Q24243146 | Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection |
| Q34546965 | Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. |
| Q35627567 | Antiviral and antiretroviral use in pregnancy |
| Q33817221 | Appropriate feeding methods for infants of HIV infected mothers in sub-Saharan Africa |
| Q33886570 | Association of HIV diversity and survival in HIV-infected Ugandan infants. |
| Q34592149 | Associations between peripheral Plasmodium falciparum malaria parasitemia, human immunodeficiency virus, and concurrent helminthic infection among pregnant women in Malawi |
| Q37357700 | Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretrovirals |
| Q38884954 | Attitudes to voluntary counselling and testing for HIV among pregnant women in rural south-west Uganda |
| Q37063906 | Awareness and attitudes about HIV among pregnant women in Aksu, northwest China |
| Q73854888 | Barriers to universal prenatal HIV testing in 4 US locations in 1997 |
| Q34134490 | Bayesian estimation of the time-varying sensitivity of a diagnostic test with application to mother-to-child transmission of HIV. |
| Q33865236 | Beyond prevention of mother-to-child transmission: keeping HIV-exposed and HIV-positive children healthy and alive |
| Q34122386 | Biologic approaches to the prevention of sexual transmission of human immunodeficiency virus |
| Q36836852 | Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission |
| Q34805478 | Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward |
| Q36052959 | Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine |
| Q37352276 | Breast-feeding and HIV transmission |
| Q38885069 | Breastfeeding practices and attitudes relevant to the vertical transmission of HIV in rural south-west Uganda |
| Q34790830 | CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV prevention |
| Q40539833 | Can Disease-Specific Funding Harm Health? in the Shadow of HIV/AIDS Service Expansion |
| Q30330238 | Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? |
| Q34881120 | Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers |
| Q35108744 | Challenges in delivering antiretroviral treatment in resource poor countries |
| Q37730522 | Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors |
| Q44684894 | Characterization of the main placental cytokine profiles from HIV-1-infected pregnant women treated with anti-retroviral drugs in France |
| Q42786564 | Cheaper antiretrovirals to treat AIDS in South Africa. They are at their most cost effective in preventing mother to child transmission |
| Q30397949 | Child health in Africa: 2005 a year of hope? |
| Q36279151 | Child mortality levels and trends by HIV status in Blantyre, Malawi: 1989-2009. |
| Q37143745 | Children and HIV/AIDS: from research to policy and action in resource-limited settings |
| Q36361859 | Choice of delta: requirements and reality--results of a systematic review |
| Q37075676 | Clinical Trials: Discerning Hype From Substance |
| Q37037070 | Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission |
| Q36811249 | Clinical implications of HIV-1 minority variants |
| Q34986881 | Clinical malaria diagnosis in pregnancy in relation to early perinatal mother-to-child transmission of HIV: a prospective cohort study |
| Q46912381 | Clinical manifestations and outcome in HIV-infected young infants presenting with acute illness in Durban, South Africa |
| Q33966241 | Clinical uses of non-nucleoside reverse transcriptase inhibitors |
| Q39015539 | Collection of standardized information on infant feeding in the context of mother-to-child transmission of HIV. |
| Q33763923 | Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens |
| Q35788526 | Comparison of anti-retroviral therapy treatment strategies in prevention of mother-to-child transmission in a teaching hospital in Ethiopia |
| Q37255757 | Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study |
| Q37305031 | Comparison of isotope dilution with bioelectrical impedance analysis among HIV-infected and HIV-uninfected pregnant women in Tanzania |
| Q37351429 | Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings |
| Q40674710 | Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants |
| Q36069333 | Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya |
| Q53506842 | Condom use for preventing the spread of HIV/AIDS: an ethical imperative. |
| Q45905943 | Conversations with mothers: exploring reasons for prevention of mother-to-child transmission (PMTCT) failures in the era of programmatic scale-up in Soweto, South Africa. |
| Q35947561 | Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. |
| Q37344650 | Correlates of syphilis seroreactivity among pregnant women: the HIVNET 024 Trial in Malawi, Tanzania, and Zambia |
| Q33798045 | Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women |
| Q36517778 | Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe |
| Q44789835 | Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care |
| Q39501645 | Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania |
| Q51175058 | Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic. |
| Q43712249 | Couple counselling and testing for HIV at antenatal clinics: views from men, women and counsellors |
| Q33776923 | Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study |
| Q44056432 | Curbing the Global AIDS Epidemic |
| Q27000260 | Current knowledge and future research on infant feeding in the context of HIV: basic, clinical, behavioral, and programmatic perspectives |
| Q34182238 | Current treatment options to prevent perinatal transmission of HIV. |
| Q38878356 | Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda |
| Q41922010 | Darunavir for Use in Pregnant Women with HIV. |
| Q33739249 | Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission |
| Q35107662 | Defining male support during and after pregnancy from the perspective of HIV-positive and HIV-negative women in Durban, South Africa |
| Q43946224 | Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania. |
| Q37247625 | Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR. |
| Q39101101 | Determinants of HIV counselling and testing participation in a prevention of mother-to-child transmission programme in rural Burkina Faso |
| Q45963461 | Determinants of HIV-1 shedding in the genital tract of women. |
| Q21133665 | Determinants of clinician knowledge on aging and HIV/AIDS: a survey of practitioners and policy makers in Kampala District, Uganda |
| Q73184292 | Determination of stavudine in human plasma and urine by high-performance liquid chromatography using a reduced sample volume |
| Q37382748 | Determining an optimal testing strategy for infants at risk for mother-to-child transmission of HIV-1 during the late postnatal period |
| Q28546418 | Development of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, Mozambique |
| Q33851980 | Diagnosis of HIV infection in children |
| Q35077772 | Different regions of HIV-1 subtype C env are associated with placental localization and in utero mother-to-child transmission |
| Q39171986 | Difficult choices: infant feeding experiences of HIV-positive mothers in northern Tanzania |
| Q35664125 | Discordant Impact of HLA on Viral Replicative Capacity and Disease Progression in Pediatric and Adult HIV Infection |
| Q36541747 | Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro |
| Q36606419 | Distribution of haematological and chemical pathology values among infants in Malawi and Uganda |
| Q34313201 | Does severity of HIV disease in HIV-infected mothers affect mortality and morbidity among their uninfected infants? |
| Q33982634 | Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma |
| Q33510928 | Duration, pattern of breastfeeding and postnatal transmission of HIV: pooled analysis of individual data from West and South African cohorts |
| Q58815079 | Dépistage du VIH au cours de la grossesse |
| Q37351372 | Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine |
| Q33926411 | Early weaning of HIV-exposed uninfected infants and risk of serious gastroenteritis: Findings from two perinatal HIV prevention trials in Kampala, Uganda |
| Q34048585 | Economic issues in the prevention of vertical transmission of HIV. |
| Q34443184 | Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors |
| Q36023773 | Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial |
| Q36276294 | Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. |
| Q77697505 | Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies |
| Q37438124 | Effect of prenatal and perinatal antibiotics on maternal health in Malawi, Tanzania, and Zambia |
| Q37113259 | Effect of presumptive co-trimoxazole prophylaxis on pneumococcal colonization rates, seroepidemiology and antibiotic resistance in Zambian infants: a longitudinal cohort study |
| Q34478860 | Effect of single-dose anthelmintic treatment during pregnancy on an infant's response to immunisation and on susceptibility to infectious diseases in infancy: a randomised, double-blind, placebo-controlled trial |
| Q37349292 | Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia |
| Q33818426 | Effectiveness of multidrug antiretroviral regimens to prevent mother-to-child transmission of HIV-1 in routine public health services in Cameroon |
| Q37207234 | Effectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in Uganda |
| Q28472889 | Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study |
| Q37503621 | Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women |
| Q36074119 | Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients |
| Q34491123 | Effects of maternal and infant co-infections, and of maternal immunisation, on the infant response to BCG and tetanus immunisation |
| Q34609629 | Effects of vitamins, including vitamin A, on HIV/AIDS patients |
| Q36149804 | Efficacy of Six-Week Extended-Dose Nevirapine Varies by Infant Birth Weight with Greatest Relative Efficacy in Low Birth Weight Infants |
| Q33999828 | Efficacy of a less-sensitive enzyme immunoassay (3A11-LS) for early diagnosis of human immunodeficiency virus Type 1 infection in infants |
| Q28476329 | Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial |
| Q45782342 | Efficacy of single dose nevirapine in prevention of mother to child transmission of HIV-1. |
| Q38884501 | Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial |
| Q36421344 | Elevated cytokine and chemokine levels in the placenta are associated with in-utero HIV-1 mother-to-child transmission |
| Q28478377 | Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis |
| Q28481233 | Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission |
| Q26827347 | Engagement of Traditional Healers and Birth Attendants as a Controversial Proposal to Extend the HIV Health Workforce |
| Q52123310 | Ensuring a public health impact of programs to reduce HIV transmission from mothers to infants: the place of voluntary counseling and testing. |
| Q33900810 | Epidemiology of HIV infection in the newborn |
| Q33851974 | Epidemiology of HIV/AIDS in children |
| Q36440580 | Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models |
| Q46680221 | Estimating the efficacy of interventions to prevent mother-to-child transmission of HIV in breast-feeding populations: development of a consensus methodology |
| Q36620630 | Estimating the efficacy of interventions to prevent mother-to-child transmission of human immunodeficiency virus in breastfeeding populations: comparing statistical methods |
| Q40630841 | Ethical issues in clinical trials in developing countries |
| Q30333430 | Ethics and the AIDS pandemic in the developing world. |
| Q28388002 | Evaluating interventions for Ebola: The need for randomized trials |
| Q36160179 | Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda |
| Q33747742 | Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa |
| Q63977301 | Evaluation and treatment of the human immunodeficiency virus-1-exposed infant |
| Q37071435 | Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention |
| Q35962509 | Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria |
| Q39902088 | Exclusive Breast-feeding Protects against Mother-to-Child Transmission of HIV-1 through 12 Months of Age in Tanzania |
| Q35974392 | Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated |
| Q38875948 | Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials |
| Q39601844 | Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa |
| Q43933263 | Factors predicting uptake of voluntary counselling and testing in a real-life setting in a mother-and-child center in Ouagadougou, Burkina Faso |
| Q46686933 | Feasibility of prevention of perinatal HIV infection by nevirapine in rural areas of the northeast Democratic Republic of Congo, 2002-2004. |
| Q33230999 | Fertility desires and intentions of HIV-positive patients at a suburban specialist center. |
| Q37511353 | Field evaluation of a rapid human immunodeficiency virus (HIV) serial serologic testing algorithm for diagnosis and differentiation of HIV type 1 (HIV-1), HIV-2, and dual HIV-1-HIV-2 infections in West African pregnant women |
| Q36278985 | Field experiences integrating family planning into programs to prevent mother-to-child transmission of HIV. |
| Q46913600 | Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood |
| Q34748599 | First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial |
| Q73938047 | From research to implementation: challenges in the prevention of mother to child HIV transmission in the developing world |
| Q47736959 | Future of nonnucleoside reverse transcriptase inhibitors |
| Q34429270 | Gamma interferon production in response to Mycobacterium bovis BCG and Mycobacterium tuberculosis antigens in infants born to human immunodeficiency virus-infected mothers |
| Q34178242 | Genetic analyses of HIV-1 env sequences demonstrate limited compartmentalization in breast milk and suggest viral replication within the breast that increases with mastitis |
| Q37233881 | Genital tract infections among HIV-infected pregnant women in Malawi, Tanzania and Zambia |
| Q37460075 | Genotypic and phenotypic heterogeneity in the U3R region of HIV type 1 subtype C. |
| Q35960319 | German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008 |
| Q34122337 | Global dimensions of the AIDS epidemic: implications for prevention and care |
| Q30328098 | Global impact of human immunodeficiency virus and AIDS. |
| Q33810188 | Global voices on HIV/AIDS. Unfairness of social and economic structures affect AIDS in Africa |
| Q36656285 | Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. |
| Q37428510 | Growth and puberty in children with HIV infection |
| Q53991841 | Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5, 2001. |
| Q64129589 | HIV Drug Resistance and Mother-to-Child Transmission of HIV |
| Q30383181 | HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. |
| Q30248542 | HIV Testing Services in Africa: Are They Sustainable? |
| Q46472427 | HIV Treatment in Developing Countries |
| Q35113419 | HIV among pregnant women in Moshi Tanzania: the role of sexual behavior, male partner characteristics and sexually transmitted infections |
| Q85031985 | HIV and Pregnancy in Resource-Poor Settings |
| Q38329372 | HIV and the Millennium Development Goals |
| Q73048644 | HIV nucleoside analogues: new adverse effects on mitochondria? |
| Q46506365 | HIV positive women's perceptions of stigma in health care settings in Western Cape, South Africa |
| Q37888766 | HIV prevention in southern Africa: why we must reassess our strategies? |
| Q33552646 | HIV prevention is not enough: child survival in the context of prevention of mother to child HIV transmission |
| Q35427952 | HIV prevention research and global inequality: steps towards improved standards of care |
| Q47195761 | HIV prevention research: the ecstasy and the agony |
| Q38081072 | HIV protease inhibitors in pregnancy : pharmacology and clinical use. |
| Q36154839 | HIV rapid testing as a key strategy for prevention of mother-to-child transmission in Brazil |
| Q33266621 | HIV screening in pregnancy |
| Q35059337 | HIV viral suppression in the era of antiretroviral therapy |
| Q38473364 | HIV voluntary counselling and testing in community health services |
| Q34493678 | HIV-1 drug resistance-associated mutations among HIV-1 infected drug-naïve antenatal clinic attendees in rural Kenya |
| Q37396586 | HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission |
| Q38931978 | HIV-1 primary and secondary antiretroviral drug resistance and genetic diversity among pregnant women from central Brazil |
| Q46754103 | HIV-1 test acceptance within the prevention of mother-to-child HIV-1 transmission program in Democratic Republic of Congo |
| Q34710280 | HIV-1/AIDS and maternal and child health in Africa |
| Q35800191 | HIV-free survival among nine- to 24-month-old children born to HIV-positive mothers in the Rwandan national PMTCT programme: a community-based household survey |
| Q37293883 | HIV/AIDS and Africa's orphan crisis |
| Q36684150 | HIV/AIDS and women's health in Uganda: lingering gender inequity |
| Q33204461 | HIV/AIDS in Asia |
| Q33446714 | HIV: mother-to-child transmission |
| Q33866493 | HIV: prevention of mother-to-child transmission. |
| Q45015792 | HIVNET nevirapine trials |
| Q58417656 | HIVNET nevirapine trials |
| Q73218315 | HIVNET nevirapine trials |
| Q45273875 | Haematological changes in African children who received short-term prophylaxis with nevirapine and zidovudine at birth |
| Q35825690 | Health outcomes of HIV-exposed uninfected African infants |
| Q64083479 | Healthcare worker experiences with Option B+ for prevention of mother-to-child HIV transmission in eSwatini: findings from a two-year follow-up study |
| Q34783368 | Hepatitis C virus infection in children coinfected with HIV: epidemiology and management |
| Q37399082 | Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. |
| Q36008539 | Hepatotoxicity of antiretrovirals: incidence, mechanisms and management |
| Q36344179 | High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting |
| Q34161950 | Historical essay. Prospects for the future |
| Q37136224 | History of the prevention of mother-to-child transmission of HIV in Thailand |
| Q58106377 | Home deliveries: Implications for adherence to nevirapine in a PMTCT programme in rural Malawi |
| Q38457057 | Home-based care for orphaned children infected with HIV/AIDS in Uganda. |
| Q33575664 | Host genetic determinants of human immunodeficiency virus infection and disease progression in children |
| Q38062206 | How the global call for elimination of pediatric HIV can support HIV-positive women to achieve their pregnancy intentions |
| Q39232372 | Human immuno-deficiency virus and infant feeding in complex humanitarian emergencies: priorities and policy considerations |
| Q36561178 | Human immunodeficiency virus (HIV) in developing countries. |
| Q45363198 | Human immunodeficiency virus type 1 mother-to-child transmission and prevention: successes and controversies. |
| Q34737547 | Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides |
| Q31093697 | Human immunodeficiency virus-specific CD8(+) T cells in human breast milk |
| Q36315692 | Human immunodeficiency virus-specific CD8+ T-cell activity is detectable from birth in the majority of in utero-infected infants |
| Q44704539 | Human immunodeficiency virus: current pregnancy aspects |
| Q36950113 | Identification of Ugandan HIV type 1 variants with unique patterns of recombination in pol involving subtypes A and D. |
| Q35988859 | Identification of gaps for implementation science in the HIV prevention, care and treatment cascade; a qualitative study in 19 districts in Uganda |
| Q37245203 | Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. |
| Q34462107 | Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. |
| Q37356088 | Impact of HLA in mother and child on disease progression of pediatric human immunodeficiency virus type 1 infection |
| Q36274941 | Impact of placental Plasmodium falciparum malaria on pregnancy and perinatal outcome in sub-Saharan Africa: I: introduction to placental malaria |
| Q33380234 | Impact of placental Plasmodium falciparum malaria on pregnancy and perinatal outcome in sub-Saharan Africa: part III: placental malaria, maternal health, and public health. |
| Q57951606 | Implementing anti-retroviral triple therapy to prevent HIV mother-to-child transmission: a public health approach in resource-limited settings |
| Q24647732 | Implementing programs for the prevention of mother-to-child HIV transmission in resource-constrained settings: Horizons studies, 1999-2007 |
| Q33810830 | Improving child health: the role of research |
| Q33515131 | Improving the coverage of the PMTCT programme through a participatory quality improvement intervention in South Africa |
| Q37364479 | In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. |
| Q36632220 | In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers |
| Q42245051 | In-home HIV testing and nevirapine dosing by traditional birth attendants in rural Zambia: a feasibility study. |
| Q37322060 | Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic |
| Q64069380 | Incidence, prevalence and associated factors of mother-to-child transmission of HIV, among children exposed to maternal HIV, in Belgaum district, Karnataka, India |
| Q34631738 | Incident pregnancy and time to death or AIDS among HIV-positive women receiving antiretroviral therapy |
| Q37439907 | Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure |
| Q35037981 | Increased risk of severe infant anemia after exposure to maternal HAART, Botswana |
| Q35846256 | Independent effects of nevirapine prophylaxis and HIV-1 RNA suppression in breast milk on early perinatal HIV-1 transmission |
| Q34699162 | Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children |
| Q35889975 | Infant feeding practice and associated factors of HIV positive mothers attending prevention of mother to child transmission and antiretroviral therapy clinics in Gondar Town health institutions, Northwest Ethiopia |
| Q42040467 | Infant feeding practices in complex emergencies: a case study approach. |
| Q36049152 | Infant feeding practices of women in a perinatal HIV-1 prevention study in Nairobi, Kenya |
| Q40220544 | Influence of the involvement of partners in the mother class with voluntary confidential counselling and testing acceptance for prevention of mother to child transmission of HIV programme (PMTCT programme) in Cambodia |
| Q39670900 | Integrating prevention of mother-to-child HIV transmission into antenatal care: learning from the experiences of women in South Africa |
| Q34975110 | Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals |
| Q33906773 | Interventions aimed at decreasing the risk of mother-to-child transmission of HIV infection |
| Q24241793 | Interventions for preventing late postnatal mother-to-child transmission of HIV |
| Q36295462 | Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog |
| Q38882753 | Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. |
| Q37393041 | Intrapartum antibiotic exposure and early neonatal, morbidity, and mortality in Africa |
| Q37730650 | Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia |
| Q24796704 | Is the "3 by 5" initiative the best approach to tackling the HIV pandemic? |
| Q51932863 | Large-sample Bayesian posterior distributions for probabilistic sensitivity analysis. |
| Q94272417 | Le dépistage du VIH pendant la grossesse |
| Q44588127 | Long-term findings of HIVNET 012: the next steps |
| Q34179093 | Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease |
| Q36054956 | Longitudinal comparison of chemokines in breastmilk early postpartum among HIV-1-infected and uninfected Kenyan women |
| Q30486379 | Loss to Followup: A Major Challenge to Successful Implementation of Prevention of Mother-to-Child Transmission of HIV-1 Programs in Sub-Saharan Africa |
| Q53609099 | Low absolute neutrophil counts in African infants. |
| Q39850956 | Low male partner participation in antenatal HIV counselling and testing in northern Tanzania: implications for preventive programs |
| Q44644328 | Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaoundé, Cameroon |
| Q34761065 | Low rates of mother-to-child HIV transmission in a routine programmatic setting in Lilongwe, Malawi |
| Q36060517 | Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment |
| Q94352872 | L’évaluation et le traitement du nourrisson exposé au virus d’immunodéficience humaine de type 1 |
| Q79327986 | Management of Antiretroviral Therapy in Neonates, Children, and Adolescents |
| Q37608356 | Managing mother-to-child transmission of HIV infection in developed-country settings |
| Q26778504 | Maraviroc: a review of its use in HIV infection and beyond |
| Q37068923 | Maternal HIV infection and other factors associated with growth outcomes of HIV-uninfected infants in Entebbe, Uganda |
| Q38853302 | Maternal Influences on Access to and Use of Infant ARVs and HIV Health Services in Uganda |
| Q36866309 | Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial |
| Q46967461 | Maternal common mental disorder and infant growth--a cross-sectional study from Malawi |
| Q36231035 | Maternal or infant antiretroviral drugs to reduce HIV-1 transmission |
| Q24804378 | Maternal plasma viral load and neutralizing/enhancing antibodies in vertical transmission of HIV: a non-randomized prospective study |
| Q36743918 | Maternal-fetal DNA admixture is associated with intrapartum mother-to-child transmission of HIV-1 in Blantyre, Malawi |
| Q24810804 | Maternal-fetal microtransfusions and HIV-1 mother-to-child transmission in Malawi |
| Q34151052 | Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques |
| Q36671008 | Medical records and women's self-report are not reliable sources for determining whether prenatal HIV testing was done. |
| Q54212657 | Medicinal Plants Used in the Treatment of Human Immunodeficiency Virus. |
| Q39569701 | Meeting international goals in child survival and HIV/AIDS. |
| Q36460440 | Microbicides and other topical strategies to prevent vaginal transmission of HIV. |
| Q90236461 | Mid-trimester cervical length not associated with HIV status among pregnant women in Botswana |
| Q36398171 | Missed opportunities for participation in prevention of mother to child transmission programmes: simplicity of nevirapine does not necessarily lead to optimal uptake, a qualitative study |
| Q42947688 | Modeling interventions to assess HIV epidemic impact in Africa |
| Q37464854 | Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi |
| Q34626428 | Molecular mechanisms of HIV-1 mother-to-child transmission and infection in neonatal target cells |
| Q37034644 | Molecular mechanisms of HIV-1 vertical transmission and pathogenesis in infants |
| Q37108553 | Monitoring effectiveness of programmes to prevent mother-to-child HIV transmission in lower-income countries |
| Q44565712 | Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1. |
| Q37336328 | Morbidity and mortality among a cohort of human immunodeficiency virus type 1-infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania |
| Q38699481 | Mother-to-Child HIV Transmission Bottleneck Selects for Consensus Virus with Lower Gag-Protease-Driven Replication Capacity |
| Q37798996 | Mother-to-child transmission of HIV-1 in sub-Saharan Africa: Past, present and future challenges |
| Q36635880 | Mother-to-child transmission of HIV-1: timing and implications for prevention |
| Q45200255 | Mother-to-child transmission of HIV: a global perspective |
| Q37259828 | Mother-to-child transmission of HIV: findings from an early infant diagnosis program in Bertoua, Eastern Cameroon |
| Q36010792 | Mother-to-infant transmission of HIV-1: the placenta fights back |
| Q43960653 | Mothers, orphans, and prevention of paediatric AIDS. |
| Q36398541 | Multiple micronutrient supplementation in Tanzanian infants born to HIV-infected mothers: a randomized, double-blind, placebo-controlled clinical trial |
| Q37098421 | Multivitamin supplementation improves haematologic status in children born to HIV-positive women in Tanzania |
| Q37082283 | Multivitamin supplements have no effect on growth of Tanzanian children born to HIV-infected mothers |
| Q33853597 | Narrowing the gap: access to HIV treatments in developing countries. A pharmaceutical company's perspective |
| Q40003689 | Neurodevelopmental impairment among infants born to mothers infected with human immunodeficiency virus and uninfected mothers from three peri-urban primary care clinics in Harare, Zimbabwe |
| Q35599864 | Nevirapine to prevent mother-to-child transmission of HIV-1 among women of unknown serostatus |
| Q80408899 | Nevirapine use to reduce mother-to-child transmission of HIV in Canada |
| Q33582646 | Nevirapine use to reduce mother-to-child transmission of HIV in Canada. |
| Q46524400 | Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya |
| Q34055828 | Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection |
| Q73591243 | Nevirapine: an option for preventing as well as treating paediatric HIV infection |
| Q34078483 | Nevirapine: pharmacokinetic considerations in children and pregnant women |
| Q33567227 | Non-adherence to the single dose nevirapine regimen for the prevention of mother-to-child transmission of HIV in Bindura town, Zimbabwe: a cross-sectional analytic study |
| Q34481618 | Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection |
| Q92967070 | Nonoccupational Postexposure Prophylaxis and Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention in Adolescents and Young Adults |
| Q45046880 | Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients |
| Q36933747 | Nutrition and HIV/AIDS in infants and children in South Africa: implications for food-based dietary guidelines |
| Q36775774 | Nutritional indicators of adverse pregnancy outcomes and mother-to-child transmission of HIV among HIV-infected women |
| Q43927398 | Nutritional status and complementary feeding among HIV-exposed infants: a prospective cohort study |
| Q58101689 | On the fault-line: The politics of AIDS policy in contemporary South Africa |
| Q64102760 | Option B+ prevention of mother-to-child transmission of HIV/AIDS service intervention outcomes in selected health facilities, Adama town, Ethiopia |
| Q34574291 | Options for prevention of HIV transmission from mother to child, with a focus on developing countries |
| Q37381591 | Outcome of Different Nevirapine Administration Strategies in Preventin g Mother-to-Child Transmission (PMTCT) Programs in Tanzania and Uganda |
| Q38879121 | Outcome of different nevirapine administration strategies in preventing mother-to-child transmission (PMTCT) programs in Tanzania and Uganda. |
| Q35878689 | Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. |
| Q59944808 | Oxidation of 2-Hydroxynevirapine, a Phenolic Metabolite of the Anti-HIV Drug Nevirapine: Evidence for an Unusual Pyridine Ring Contraction |
| Q33744042 | Paediatric HIV-1 infection |
| Q34374691 | Parent to child transmission of HIV: policy considerations in the Asia-Pacific region |
| Q35867981 | Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. |
| Q34876113 | Pediatric HIV infection and treatment |
| Q36241441 | Pediatric human immunodeficiency virus-1 infection |
| Q33974239 | Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda |
| Q35670412 | Performance of HIV Prevention of Mother-To-Child Transmission Programs in Sub-Saharan Africa: Longitudinal Assessment of 64 Nevirapine-Based Programs Implemented in 25 Countries, 2000-2011. |
| Q37809603 | Perinatal HIV and Its Prevention: Progress Toward an HIV-free Generation |
| Q36994530 | Perinatal HIV-1 transmission: Fc gamma receptor variability associates with maternal infectiousness and infant susceptibility |
| Q40695398 | Perinatal Transmission of HIV: Recognition and Treatment Interventions |
| Q34065414 | Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months |
| Q34598577 | Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission |
| Q35598502 | Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants |
| Q35965780 | Pharmacokinetics of antiretrovirals in pregnant women |
| Q34922985 | Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants |
| Q33983697 | Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates |
| Q35557216 | Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy |
| Q36410952 | Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations |
| Q74023464 | Pharmacological implications of lengthened in-utero exposure to nevirapine |
| Q36166932 | Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial |
| Q41495263 | Placebo orthodoxy and the double standard of care in multinational clinical research |
| Q44234789 | Placental cytokine and chemokine production in HIV-1-infected women: trophoblast cells show a different pattern compared to cells from HIV-negative women |
| Q37178422 | Placental malaria and mother-to-child transmission of human immunodeficiency virus-1. |
| Q34914391 | Population attributable fractions for late postnatal mother-to-child transmission of HIV-1 in Sub-Saharan Africa |
| Q38865904 | Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns |
| Q92368862 | Population uptake and effectiveness of test-and-treat antiretroviral therapy guidelines for preventing the global spread of HIV: an ecological cross-national analysis |
| Q35871549 | Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting |
| Q40720534 | Postnatal care utilization and local understandings of contagion among HIV-infected and uninfected women in rural, southern Zambia. |
| Q33749434 | Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy |
| Q38051400 | Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. |
| Q33335347 | Potential impact of infant feeding recommendations on mortality and HIV-infection in children born to HIV-infected mothers in Africa: a simulation |
| Q36872933 | Pre-exposure prophylaxis for HIV infection: what if it works? |
| Q38463936 | Predictors of HIV seropositivity following intrapartum voluntary counseling and testing among Rwandan women |
| Q43950760 | Predictors of HIV-1 serostatus disclosure: a prospective study among HIV-infected pregnant women in Dar es Salaam, Tanzania. |
| Q37399196 | Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda. |
| Q35759201 | Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmission |
| Q26825042 | Preexposure prophylaxis for HIV prevention: where have we been and where are we going? |
| Q28741879 | Pregnancy and virologic response to antiretroviral therapy in South Africa |
| Q36296734 | Pregnancy decisions among women with HIV |
| Q33719217 | Pregnancy does not affect HIV incidence test results obtained using the BED capture enzyme immunoassay or an antibody avidity assay |
| Q58164877 | Pregnant women's decisions on antenatal HIV screening in Hong Kong |
| Q83668542 | Prenatal screening and perinatal HIV transmission in Northern Alberta, 1999-2006 |
| Q35079662 | Presumptive diagnosis of severe HIV infection to determine the need for antiretroviral therapy in children less than 18 months of age. |
| Q36833511 | Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis |
| Q34226031 | Prevalent pregnancy, biological sex, and virologic response to antiretroviral therapy |
| Q42656627 | Preventing HIV |
| Q34467080 | Preventing Mother To Child Transmission of HIV - Current strategies |
| Q53480914 | Preventing mother-to-child transmission of HIV in developing countries: recent developments and ethical implications. |
| Q81784492 | Preventing mother-to-child transmission of HIV in resource-limited settings: the Elizabeth Glaser Pediatric AIDS Foundation experience |
| Q39279623 | Preventing mother-to-child transmission: factors affecting mothers' choice of feeding--a case study from Cameroon |
| Q34488330 | Preventing perinatal transmission of HIV: an evidence-based update for midwives |
| Q45932455 | Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. |
| Q33852019 | Prevention of HIV infection in children |
| Q40246904 | Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants |
| Q46621999 | Prevention of mother to child HIV-1 transmission (MTC) in Cameroon |
| Q35744326 | Prevention of mother to child transmission of HIV. |
| Q34722182 | Prevention of mother-to-child HIV transmission in resource-limited settings: assessment of 99 Viramune Donation Programmes in 34 countries, 2000-2011. |
| Q28083088 | Prevention of mother-to-child transmission in South Africa: an ever-changing landscape |
| Q37351420 | Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia |
| Q43944991 | Prevention of mother-to-child transmission of HIV in a refugee camp setting in Tanzania |
| Q37805763 | Prevention of mother-to-child transmission of HIV in resource-rich and -poor settings |
| Q35751105 | Prevention of mother-to-child transmission of HIV type 1: the role of neonatal and infant prophylaxis |
| Q35207628 | Prevention of perinatal HIV transmission: a review of novel strategies |
| Q34967071 | Prevention of perinatal HIV transmission: current status and future developments in anti-retroviral therapy |
| Q22241479 | Prevention of vertical transmission of HIV-1 in resource-limited settings |
| Q37366088 | Primary HIV-1 infection among infants in sub-Saharan Africa: HPTN 024. |
| Q33797464 | Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. |
| Q43979551 | Provider-related barriers to rapid HIV testing in U.S. urban non-profit community clinics, community-based organizations (CBOs) and hospitals |
| Q43956302 | Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (revised November 3, 2000). |
| Q35598505 | Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. |
| Q33514943 | RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy |
| Q36775790 | Randomized, double-blind, placebo-controlled trial of selenium supplements among HIV-infected pregnant women in Tanzania: effects on maternal and child outcomes |
| Q36619812 | Rapid HIV testing: a review of the literature and implications for the clinician |
| Q34925139 | Rapid intrapartum or postpartum HIV testing at a midwife obstetric unit and a district hospital in South Africa |
| Q33378905 | Rapid testing may not improve uptake of HIV testing and same day results in a rural South African community: a cohort study of 12,000 women |
| Q43120703 | Recent advances in prevention of mother to child (PMTCT) of HIV. |
| Q33805905 | Recent advances: Paediatrics |
| Q73980863 | Recent developments in the treatment of HIV disease |
| Q45876260 | Recent trends in mother to child transmission of HIV in pregnancy |
| Q35082917 | Reduced HIV transmission at subsequent pregnancy in a resource-poor setting |
| Q34191977 | Reducing mother-to-child transmission of HIV: findings from an early infant diagnosis program in south-south region of Nigeria. |
| Q33919699 | Reducing perinatal transmission of HIV: early diagnosis and interventions during pregnancy |
| Q46010872 | Reducing vertical HIV transmission in Kinshasa, Democratic Republic of Congo: trends in HIV prevalence and service delivery. |
| Q43933355 | Reduction of mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso |
| Q33807209 | Regular review: HIV infection in children |
| Q38885081 | Relation of vitamin A and carotenoid status to growth failure and mortality among Ugandan infants with human immunodeficiency virus |
| Q34777347 | Research priorities for the reduction of perinatal and neonatal morbidity and mortality in developing country communities |
| Q24634420 | Research translation to inform national health policies: learning from multiple perspectives in Uganda |
| Q43122787 | Rising mother-to-child HIV transmission in a resource-limited breastfeeding population |
| Q38884540 | Risk factors and cumulative incidence of anaemia among human immunodeficiency virus-infected children in Uganda. |
| Q37314814 | Risk factors for late postnatal transmission of human immunodeficiency virus type 1 in sub-Saharan Africa |
| Q34365310 | Risk factors of HIV vertical transmission in a cohort of women under a PMTCT program at three peri-urban clinics in a resource-poor setting |
| Q43946994 | Risk of HIV-1 transmission by breastfeeding among mothers infected with recombinant and non-recombinant HIV-1 genotypes |
| Q35021860 | Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine |
| Q33808843 | Role of traditional birth attendants in preventing perinatal transmission of HIV. |
| Q37084616 | Routine offer of antenatal HIV testing ("opt-out" approach) to prevent mother-to-child transmission of HIV in urban Zimbabwe |
| Q28346130 | SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2 |
| Q35475930 | Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). |
| Q33944686 | Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa |
| Q32068631 | Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women |
| Q57180244 | Safety of nevirapine in pregnancy |
| Q37587520 | Saving the lives of South Africa's mothers, babies, and children: can the health system deliver? |
| Q34645009 | Scaling up prevention of mother-to-child HIV transmission programs in sub-Saharan African countries: a multilevel assessment of site-, program- and country-level determinants of performance |
| Q36726535 | Scope of rapid HIV testing in urban U.S. hospitals |
| Q37370674 | Selection of HIV variants with signature genotypic characteristics during heterosexual transmission |
| Q33425307 | Sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of stavudine in human plasma |
| Q35947480 | Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies |
| Q33972240 | Sensitivity and specificity of human immunodeficiency virus rapid serologic assays and testing algorithms in an antenatal clinic in Abidjan, Ivory Coast |
| Q35790256 | Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. |
| Q35018936 | Sero-conversion rate of Syphilis and HIV among pregnant women attending antenatal clinic in Tanzania: a need for re-screening at delivery |
| Q36238297 | Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hépatites Virales 1209 study, Abidjan, Ivory Coast |
| Q92543920 | Serum n-6 Fatty Acids are Positively Associated with Growth in 6-to-10-Year Old Ugandan Children Regardless of HIV Status-A Cross-Sectional Study |
| Q35697252 | Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study |
| Q35531854 | Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. |
| Q42535693 | Short communication: CD8(+) T cell polyfunctionality profiles in progressive and nonprogressive pediatric HIV type 1 infection |
| Q36634965 | Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes |
| Q44625140 | Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial |
| Q83369592 | Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women |
| Q35149835 | Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments |
| Q36154492 | Short-term mortality and implementation of antiretroviral treatment for critically ill HIV-infected children in a developing country |
| Q80690454 | Should emergency departments offer postexposure prophylaxis for non-occupational exposure to HIV? |
| Q45180318 | Simple detection of point mutations associated with HIV-1 drug resistance. |
| Q42551176 | Single-dose nevirapine exposure affects T cell response and cytokine levels in HIV type 1-infected women |
| Q35145366 | Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission |
| Q35625281 | Special considerations for the HIV-infected patient with preterm labor |
| Q43922207 | Stage of the epidemic and viral phenotype should influence recommendations regarding mother-to-child transmission of HIV-1. |
| Q35052260 | State-of-the-Art HIV Management:An Update |
| Q39234478 | Strategies for prevention of mother-to-child transmission of HIV. |
| Q36315555 | Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy |
| Q24805098 | T lymphocytes among HIV-infected and -uninfected infants: CD4/CD8 ratio as a potential tool in diagnosis of infection in infants under the age of 2 years |
| Q40191155 | Tackling HIV and AIDS: contributions by non-human primate models |
| Q33686897 | Temporal reduction of HIV type 1 viral load in breast milk by single-dose nevirapine during prevention of MTCT |
| Q83408280 | Testing for HIV infection in pregnancy |
| Q82557193 | Testing for human immunodeficiency virus type 1 (HIV-1) infection in pregnancy |
| Q35580656 | The 30-year war on AIDS: have we reached the tipping point? |
| Q28140757 | The Durban Declaration |
| Q57463352 | The Effect of Absenteeism and Clinic Protocol on Health Outcomes: The Case of Mother-to-Child Transmission of HIV in Kenya |
| Q35111300 | The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection |
| Q30250286 | The History of the HIV/AIDS Epidemic in Africa |
| Q90274970 | The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic |
| Q34498482 | The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum women |
| Q34554572 | The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic |
| Q36059796 | The effect of anthelmintic treatment during pregnancy on HIV plasma viral load: results from a randomized, double-blind, placebo-controlled trial in Uganda |
| Q36049008 | The effect of rapid HIV-1 testing on uptake of perinatal HIV-1 interventions: a randomized clinical trial |
| Q46619156 | The epidemiology and pathophysiology of HIV--as seen by a South African |
| Q35140408 | The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population |
| Q30558707 | The impact of Fogarty International Center research training programs on public health policy and program development in Kenya and Uganda |
| Q37098916 | The impact of helminths on the response to immunization and on the incidence of infection and disease in childhood in Uganda: design of a randomized, double-blind, placebo-controlled, factorial trial of deworming interventions delivered in pregnancy |
| Q37383272 | The molecular epidemiology of HIV-1 envelope diversity during HIV-1 subtype C vertical transmission in Malawian mother-infant pairs |
| Q34982693 | The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques |
| Q30374404 | The rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies |
| Q35000080 | The role of cell-associated virus in mother-to-child HIV transmission |
| Q35542406 | The role of co-infections in mother-to-child transmission of HIV. |
| Q34425821 | The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection |
| Q22241890 | The spread, treatment, and prevention of HIV-1: evolution of a global pandemic |
| Q58663635 | The standard of care debate: can research in developing countries be both ethical and responsive to those countries' health needs? |
| Q36662110 | Three postpartum antiretroviral regimens to prevent intrapartum HIV infection |
| Q37351379 | Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine |
| Q34323709 | Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. |
| Q37290917 | Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children. |
| Q34405657 | Toward elimination of perinatal HIV transmission: New Jersey hospital barriers to rapid HIV testing in labor and delivery, 2005. |
| Q37815331 | Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease |
| Q36497045 | Treating HIV during pregnancy: an update on safety issues |
| Q36193376 | Treating HIV-infected mothers reduces under 5 years of age mortality rates to levels seen in children of HIV-uninfected mothers in rural South Africa |
| Q35672479 | Treatment of HIV infection in pregnant women: antiretroviral management options. |
| Q34585177 | Treatment of sexually transmitted infections with single-dose therapy: a double-edged sword |
| Q57826130 | Trends in Neonatal Prophylaxis and Predictors of Combination Antiretroviral Prophylaxis in US Infants from 1990 to 2015 |
| Q51893238 | Trends in perinatal HIV prevention in New York City, 1994-2003. |
| Q34322143 | Two commentaries on 'Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children' |
| Q33827841 | Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance |
| Q35842613 | Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings |
| Q37351394 | Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings |
| Q51162932 | Universal prenatal HIV screening: are we there yet? |
| Q33851977 | Update on perinatal HIV transmission |
| Q36445640 | Update: preventing mother-to-child transmission of HIV. |
| Q35856509 | Uptake of prevention of mother to child transmission interventions in Kenya: health systems are more influential than stigma |
| Q39024291 | Use of UNAIDS tools to evaluate HIV voluntary counselling and testing services for mineworkers in South Africa |
| Q36816377 | Use of antiretrovirals for HIV prevention: what do we know and what don't we know? |
| Q34294499 | Use of service data to inform pediatric HIV-free survival following prevention of mother-to-child transmission programs in rural Malawi |
| Q35116953 | Using formative research to develop a context-specific approach to informed consent for clinical trials |
| Q42991840 | Utilization of therapeutic intervention to prevent mother to child transmission of HIV in a teaching hospital in Kolkata, India |
| Q36557330 | Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities |
| Q39900727 | Validation of the Edinburgh Postnatal Depression Scale among women in a high HIV prevalence area in urban Zimbabwe |
| Q39598934 | Vertical HIV transmission in South Africa: translating research into policy and practice |
| Q41933352 | Vertical transmission of hepatitis C virus: variable transmission bottleneck and evidence of mid-gestation in utero infection |
| Q35219574 | Viral Sequence Analysis from HIV-Infected Mothers and Infants: Molecular Evolution, Diversity, and Risk Factors for Mother-To-Child Transmission |
| Q34162417 | Virtual Elimination of Mother-to-Child Transmission of Human Immunodeficiency Virus in Mothers on Highly Active Antiretroviral Therapy in Enugu, South-Eastern Nigeria |
| Q28478406 | WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers |
| Q88586767 | Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa |
| Q33808840 | What can we do to reduce mother to child transmission of HIV? |
| Q37764907 | What is new in HIV/AIDS research in developing countries? |
| Q48521585 | What is new in perinatal HIV prevention? |
| Q28478769 | What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis |
| Q73854875 | Where is the M in MTCT? The broader issues in mother-to-child transmission of HIV |
| Q46204047 | Women identified with HIV at labor and delivery: testing, disclosing and linking to care challenges |
| Q42245662 | Women's choices regarding HIV testing, disclosure and partner involvement in infant feeding and care in a rural district of Malawi with high HIV prevalence. |
| Q37509507 | Women's reasons for not participating in follow up visits before starting short course antiretroviral prophylaxis for prevention of mother to child transmission of HIV: qualitative interview study |
| Q43804992 | Zambian women's attitudes toward mass nevirapine therapy to prevent perinatal transmission of HIV. |
| Q42167560 | Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. |
| Q34749066 | Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection |
| Q43947231 | Zinc supplementation to HIV-1-infected pregnant women: effects on maternal anthropometry, viral load, and early mother-to-child transmission |
| Q74298959 | [Is it possible to eradicate vertical transmission of HIV infection?] |
| Q74021275 | [Medically assisted reproduction and the desire for a child by HIV infected couples: has the time for a change in attitude come?]] |
| Q54015382 | [New strategies for antiretroviral treatment in HIV infected patients] |
| Q73978010 | [Pharmacology of antiretroviral agents in children] |
| Q77363100 | [Prevention of vertical transmission and treatment of infection caused by the human immunodeficiency virus in the pregnant woman. Recommendations of the Study Group for AIDS, Infectious Diseases, and Clinical Microbiology, the Spanish Pediatric Asso |
| Q53966961 | [Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002]. |
Search more.